As an inhibitor of Ca 2+ release through ryanodine receptor (RYR) channels, the skeletal muscle relaxant dantrolene has proven to be both a valuable experimental probe of 
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INTRODUCTION
Ryanodine receptors (RYRs) are intracellular Ca 2+ channels specialized for the rapid and massive release of Ca 2+ , as is necessary for excitation-contraction (EC) coupling in striated muscle (1) . Three different RYR isoforms have been identified in mammalian tissues: the RYR1, which is predominantly expressed in skeletal muscle; the RYR2, which is predominantly expressed in cardiac muscle; and the RYR3, which is expressed at comparatively low levels in a variety of tissues, including the brain. Because RYR channels play critical roles in the diverse physiologic/pathophysiologic cell processes that are controlled by Ca 2+ release from intracellular stores (2), these channels represent potentially important pharmacologic targets for modulating cell regulation (3) . However, the key functional properties that may distinguish the different RYR isoforms remain unclear (4, 5) , and few if any drugs are known to act as isoform-specific modulators of these channels (3).
To date, the muscle relaxant dantrolene remains the only drug targeting RYR channels that is used clinically (3, 5) . Early investigations indicated that dantrolene may act selectively on the physiologic mechanism responsible for activating Ca 2+ release from the sarcoplasmic reticulum (SR) during skeletal muscle EC coupling (6, 7, 8) . Accordingly, dantrolene (~10 µM) shifts the sensitivity of contractile activation to higher voltages and reduces skeletal muscle twitch force by more than half (7, 8) . Dantrolene inhibition of SR Ca 2+ release in skeletal muscle has provided a lifesaving treatment for the pharmacogenetic disorder malignant hyperthermia (MH). Thus, the uncontrolled SR Ca 2+ release, muscle contracture, and accelerated metabolism that threaten the MH-susceptible (MHS) patient exposed to volatile anesthetics during surgery are effectively suppressed upon treatment with dantrolene (9, 10) . Dantrolene also reverses the increased sensitivity of MHS muscle to activation by caffeine (11) , which constitutes the basis of in vitro diagnostic tests of this syndrome (12, 13 ). Dantrolene's efficacy in the treatment of MH is in large part a function of this drug's selective action on SR Ca 2+ release in skeletal muscle, while exerting no comparable negative inotropic effect on the beating heart (6, 10, 14) . Notably, the absence of major effects of dantrolene on SR Ca 2+ release in the heart is consistent with the possibility that dantrolene may act selectively on the RYR1 but not the RYR2 channel isoform (15) . At the same time, it is also clear that dantrolene's effects on Ca 2+ release from intracellular stores are not strictly limited to skeletal muscle, but extend to certain non-muscle cells, including central neurons (16) (17) (18) (19) . The basis of dantrolene's effects in non-muscle cells remains unclear, M0:06104   Page 4 however, due to uncertainty regarding the precise molecular mechanism of dantrolene inhibition, and the selectivity of this mechanism for different Ca 2+ release channel isoforms.
In a previous report, we demonstrated that dantrolene acts directly on the RYR1 to reduce the extent of channel activation by calmodulin (CaM), and thereby decrease the Ca 2+ sensitivity of channel activation (15) . Here we further define the mechanism and isoform selectivity of dantrolene as an inhibitor of RYR channels.
EXPERIMENTAL PROCEDURES
MHS pigs homozygous for the RYR1 Arg 615 →Cys mutation were obtained from the University of Minnesota Experimental Farm; normal control animals were obtained from commercial suppliers. Skeletal muscle SR vesicles were prepared from longissimus dorsi muscle of MHS and normal pigs, and cardiac SR vesicles were prepared from porcine ventricular tissue, as described previously (20, 21 Fig. 4C ; Table I ).
A comparison of the dose dependence of dantrolene inhibition at different [AMPPCP] also indicated that RYR1 inhibition was strictly dependent on adenine nucleotide (Fig. 4C) when AMPPCP was omitted from the binding media (Fig. 6C) . These results thus indicate that dantrolene inhibition of the RYR3 isoform exhibited properties similar to those previously demonstrated for the dantrolene inhibition of the RYR1 isoform in SR vesicles (15; Fig. 4 ).
DISCUSSION
Despite dantrolene's importance both in the treatment of MH, and as a pharmacologic probe of Ca 2+ release from intracellular stores, the molecular basis and specificity of dantrolene's actions on RYR channels have remained uncertain. In this study, we have used [ 3 H]ryanodine binding to further characterize the mechanism by which dantrolene may selectively inhibit the RYR1 but not the RYR2 channel isoform, and to determine whether the RYR3 isoform may also be a target for dantrolene action.
Dantrolene opposes increased RYR1 activity resulting from the MHS Arg 615 →Cys mutation-
Although dantrolene is only a partial inhibitor of the isolated RYR1, the current results clearly demonstrate that the magnitude of dantrolene's effect on the functional activity of this channel is comparable to the effect of the MHS RYR1 Arg 615 →Cys mutation. Thus, dantrolene effectively opposed the ~3-fold increase in the affinity of SR vesicle [ 3 H]ryanodine binding resulting from the MHS mutation (Fig. 1) . Dantrolene similarly opposed the ~2-fold increase in RYR1 caffeine sensitivity resulting from the MHS mutation (Fig. 2) . Increased RYR1 caffeine sensitivity is diagnostic for human MHS mutations at diverse sites in the primary sequence of the channel protein (12) , and this result is therefore consistent with dantrolene's general efficacy in the treatment of this genetically heterogeneous disorder. The basis of the increased caffeine sensitivity of MHS channels is uncertain (29) , but is unlikely to reflect actual effects of the various mutations on the affinity of caffeine binding to the RYR1 (35) . Rather, increased caffeine sensitivity may indicate that MHS mutations, like caffeine, act by reducing the threshold for RYR1 activation by Ca 2+ (29) . In this view, the observed 2-to 3-fold increase in the caffeine EC 50 in the presence of dantrolene is consistent with the 2-to 3-fold shifts in the sensitivity of MHS and normal channels to both Ca 2+ (15) and Sr 2+ (Fig. 3B) Isoform-specific action of dantrolene on RYR channels-Accumulating evidence now supports a model in which dantrolene's effects on SR Ca 2+ release in skeletal muscle may be explained by the direct binding of dantrolene to the RYR1 channel protein, without invoking putative non-RYR dantrolene receptors (26) . Accordingly, purified, solubilized preparations of the RYR1 channel protein retain sensitivity to dantrolene (15) , and crosslinking experiments have identified the RYR1 as the major SR protein labeled with a photoaffinity dantrolene analogue (33) . Nonetheless, the explanation for the dantrolene insensitivity of EC coupling in cardiac muscle has remained uncertain. For example, cardiac insensitivity to dantrolene might potentially be explained by a difference in the dantrolene binding properties of the RYR2 isoform itself, or by some cardiac-specific modification of the RYR2 protein, or by other differences in the molecular machinery that controls SR Ca 2+ release in cardiac as compared to skeletal muscle. We therefore investigated possible effects of dantrolene on the RYR2 isoform heterologously expressed in a non-muscle cell (22) . Our results (Fig. 6A) show that the RYR2 expressed in HEK-293 cells remained insensitive to dantrolene. In comparison, the RYR3 isoform expressed in the same cell type was significantly inhibited by dantrolene. These results indicate that the RYR2 itself is intrinsically insensitive to dantrolene, and thus suggest that this isoform may lack a high-affinity dantrolene site that is present in both the RYR1 and the RYR3 isoforms. We conclude that the absence of major effects of dantrolene on SR Ca 2+ release in the heart is likely a simple function of the predominant expression of the RYR2 channel isoform in cardiac muscle.
The insensitivity of the cardiac RYR2 to dantrolene is associated with other notable differences in the regulation of this channel isoform. Thus, in comparison to both the RYR1 and the RYR3 isoforms, the RYR2 isoform is less responsive to activation by adenine nucleotide (21,24) and CaM (39, 23) . Recently, we reported that CaM together with adenine nucleotide activates the RYR1 by increasing the Ca 2+ sensitivity of the channel (39) . Conversely, dantrolene inhibits the RYR1 by reducing Ca 2+ sensitivity, via a mechanism that is dependent on both adenine nucleotide and CaM. Thus, we postulate that dantrolene's selective action on the RYR1 and RYR3 may in effect oppose the nucleotide-and CaM-dependent activation of these channel isoforms. Insets at right show normalized data to emphasize effects of the MH mutation and dantrolene on RYR1 sensitivity to the divalent cations. Data are means ± SE from four experiments comparing four MHS and three normal skeletal muscle SR vesicle preparations. (Table I) . Data are means ± SE from four cardiac SR vesicle preparations. 
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